Back in April of this year, one company that I decided to revisit was Mohawk Industries, Inc. (NYSE: MHK ). At the time, I considered this enterprise, which operates as a provider of rugs, flooring, carpets, ceramic tiles, and other similarCrude Value Insights offers you an investing service and community focused on oil and natural gas. We focus on cash flow and the companies that generate it, leading to value and growth prospects with real potential.Subscribers get to use a 50+ stock model account, in-dept ...

Alnylam Pharmaceuticals (ALNY) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the s ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Zacks ...

【 导读 】 2025年7月22日，中国资本市场这片热土上，一块名为"科创板"的"试验田"已悄然耕耘六载 春秋。6年，是筚路蓝缕的创业史，是硬核科技的淬炼场，更是创新驱动国家战略的生动注 脚。589颗"科创之星"在此汇聚，闪耀着7.3万亿市值的磅礴光芒，它们从核心技术"卡脖 子"的困境中破土，在新质生产力的浪潮里拔节，共同编织着中国产业升级与科技自立自强的 宏大叙事。 值此承前启后的重要时刻，我们特别邀约了数位深耕于科创板沃土的领航者——他们是前沿 赛道的开拓者，是实验室到生产线奇迹的缔造人。褪去资本市场的喧嚣，这些掌舵人欣然提 笔，以最真挚的笔触，为我们留下了属于这个时代的"科创心语"。此刻，让我们一同静心聆 听，这些搏击于时代潮头的灵魂之声，如何汇成推动中国科创巨轮驶向星辰大海的澎湃涛 声。 海光信息总经理沙超群 正逢科创板开市 六 周年，海光信息也即将上市满 三 年。科创板为科 技企业提供了一个更加开放、包容、高效的资本市场环境，得益于科 创板丰沃的投融资土壤以及政策 " 工具箱 " ，海光信息近年来不断在 公司治理能力、创新能力、竞争能力和经营能力上取得显著进展。 海光在芯片市场取得的长足发展，离不开 ...

Exelixis (EXEL) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on July 28. On the o ...

Core Viewpoint - Pfizer offers a high dividend yield of 7.1%, significantly above the S&P 500's 1.3% and the average healthcare stock's 1.7%, but Merck may be a better choice for dividend investors due to its more stable dividend history [1][6][12] Group 1: Company Comparison - Pfizer and Merck have similar business models, focusing on research and development to create new blockbuster drugs, supported by strong marketing and distribution systems [2][4] - Both companies have a history of making large acquisitions to enhance their drug portfolios, but their current positioning may vary based on their respective drug pipelines [5][11] Group 2: Dividend History - Pfizer has a history of 15 consecutive dividend increases, but it previously cut its dividend during the Great Recession, while Merck maintained its dividend during the same period [6][8][9] - Merck's more consistent dividend growth, despite periods of stagnation, provides a level of trust for income investors that Pfizer's past cut does not [9][12] Group 3: Investment Considerations - Both Pfizer and Merck offer portfolios of already approved drugs, allowing investors to engage in the pharmaceutical sector without needing deep industry knowledge [10][11] - For dividend investors, the historical performance of dividends is crucial, making Merck a potentially safer investment compared to Pfizer [12]

It might be prudent to make a point of collecting a little more cash in the near future, and worry a little less about growth.Does the prospect of economic uncertainty have you rethinking your portfolio? Perhaps you'd like to collect a little more cash while the economic headwinds are blowing? It's not an unreasonable concern. Plenty of other investors are already thinking more defensively than they've felt they needed to in a while.To this end, here's a closer look at five high-yielding dividend stocks to ...

Group 1 - Novo Nordisk, a leader in diabetes and weight loss drugs, has underperformed the S&P 500 index since March 30, 2025 [1] - The author has a long position in Novo Nordisk shares, indicating a belief in the company's potential [1] Group 2 - The article reflects a broader investment strategy that includes a focus on technology companies and opportunities in crypto, while also considering global markets [1]

New drugs take too long to get to market because of clinical trial bottlenecks. Two cancer doctors built AI-enabled tech to speed up the process. https://t.co/YbATOyAUyO https://t.co/YbATOyAUyO ...